# Cytokinetics (CYTK) — News

CYTK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cytk/news

## Recent headlines

- [Cytokinetics announces additional data from Acacia-HCM presented at the HFSA annual scientific meeting 2026](https://www.ainvest.com/news/cytokinetics-announces-additional-data-acacia-hcm-presented-hfsa-annual-scientific-meeting-2026-2610) — AInvest Wire, Oct 12, 2026
  Cytokinetics Inc. recently presented additional data from its Acacia-HCM trial at the 2026 Heart Failure Society of America (HFSA) annual scientific meeting. The Acacia-HCM study evaluates the company’s investigational therapy for hypertrophic cardiomyopathy, a genetic heart condition characterized…
- [Cytokinetics, Incorporated: RBC raises target price to $113 from $112](https://www.ainvest.com/news/cytokinetics-incorporated-rbc-raises-target-price-113-112-2610) — AInvest Wire, Oct 8, 2026
  RBC Capital Markets has raised its target price for Cytokinetics, Incorporated (CYTK) to $113 from $112, reflecting a slight upward adjustment in its valuation outlook for the biopharmaceutical company. The updated target suggests increased confidence in Cytokinetics' potential performance, though…
- [Cytokinetics shares up 1.4% premarket after co presents new late-stage data for heart drug at European Society of Cardiology](https://www.ainvest.com/news/cytokinetics-shares-1-4-premarket-presents-late-stage-data-heart-drug-european-society-cardiology-2608) — AInvest Wire, Aug 28, 2026
  Cytokinetics, Incorporated (Nasdaq: CYTK) reported a 1.4% increase in premarket trading following the presentation of late-stage clinical data for its heart drug, aficamten, at the European Society of Cardiology. The company announced positive topline results from the ACACIA-HCM trial, a pivotal…
- [Cytokinetics announces positive results from Acacia-HCM](https://www.ainvest.com/news/cytokinetics-announces-positive-results-acacia-hcm-2608) — AInvest Wire, Aug 28, 2026
- [Cytokinetics - seeks injunction against litigation or infringement claims on Myqorzo(aficamten) - SEC filing](https://www.ainvest.com/news/cytokinetics-seeks-injunction-litigation-infringement-claims-myqorzo-aficamten-sec-filing-2608) — AInvest Wire, Aug 13, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).